How does the move to PREVENT for ASCVD risk estimation affect aspirin use❓
📜jamanetwork.com/journals/jam…
1⃣ >80% eligible for 1ry prevention aspirin based on a PCE risk >10% would no longer be eligible w/ PREVENT
2⃣ Most current aspirin users don't qualify under either calculator
🙏🙏Immensely grateful for the generous support and guidance from Dr. Ann Marie Navar, @virani_md, @ericpetersonMD, and @dramitkhera 🙏🙏
And many thanks to @JAMAInternalMed for offering an avenue to share our findings
Here are my takeaways for the 7 most relevant and important #ESCCongress2025 for generalists
AQUATIC, HI-PRO, RETREAT-FRAIL, DIGIT-HF, DAN-RSV were most practicing changing
POTCAST was most contentious - not as billed
Do heart transplant patients always need invasive angio to screen for graft vasculopathy❓
📜authors.elsevier.com/a/1lWfA…
In this meta-analysis, CTA/PET had pretty respectable sensitivity/NPV for ruling out graft vasculopathy compared to a gold standard of invasive angiography.
Patients with a normal-ish EF could be further stratified as being at a *truly* low-risk of events or at intermediate risk depending on their rest flow.
In contrast, patients with a depressed EF had a uniformly high rate of events regardless.
🙏🙏Incredibly thankful to @almallahmo and Dr. Al Rifai for their supervision & guidance on this; and to my brilliant colleague @MariaAlwan_ 🙏🙏
And thank you to @EHJCVIEiC for allowing us to share our findings!
An incredible experience at #DDW2025! Privileged to share our work on #pancreaticcancer, Fatty Pancreas, and #colorectalcancer
With 3 oral presentations, and 3 poster presentations ✅
Immensely grateful for the mentorship and support of Dr. @SriGaddamMD 🙏🏼
New genetic analysis in 200k people over 14 years
▶️apoB + lp(a) best capture lipid-mediated CV risk
▶️LDL particle size adds no additional info when apoB is accounted for
academic.oup.com/eurheartj/a…